Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma

¹Laboratory for Pathophysiology and ²Chemotherapy Unit, Rizzoli Orthopaedic Institute, and ³Department of Human Anatomy and Musculoskeletal Pathophysiology, Section of Orthopaedic Surgery, University of Bologna, Rizzoli Orthopaedic Institute, Bologna, Italy; ⁴Department of Internal and Specialistic Medicine, Endocrinology, University of Catania, Garibaldi-Nesima Hospital, Catania, Italy; ⁵Department of Oncology, McGill University, Montreal, Quebec, Canada; and ⁶Oncology Drug Discovery, Pharmaceutical Research Institute, Bristol-Myers Squibb Co., Princeton, New Jersey

^* To whom correspondence should be addressed. E-mail: sofia.avnet{at}ior.it.

	Abstract

Despite the frequent presence of an insulin-like growth factor I receptor (IGFIR)-mediated autocrine loop in osteosarcoma (OS), interfering with this target was only moderately effective in preclinical studies. Here, we considered other members of the IGF system that might be involved in the molecular pathology of OS. We found that, among 45 patients with OS, IGF-I and IGFBP-3 serum levels were significantly lower, and IGF-II serum levels significantly higher, than healthy controls. Increased IGF-II values were associated with a decreased disease-free survival. After tumor removal, both IGF-I and IGF-II levels returned to normal values. In 23 of 45 patients, we obtained tissue specimens and found that all expressed high mRNA level of IGF-II and >IGF-I. Also, isoform A of the insulin receptor (IR-A) was expressed at high level in addition to IGFIR and IR-A/IGFIR hybrids receptors (HR^A). These receptors were also expressed in OS cell lines, and simultaneous impairment of IGFIR, IR, and Hybrid-Rs by monoclonal antibodies, siRNA, or the tyrosine kinase inhibitor BMS-536924, which blocks both IGFIR and IR, was more effective than selective anti-IGFIR strategies. Also, anti–IGF-II-siRNA treatment in low-serum conditions significantly inhibited MG-63 OS cells that have an autocrine circuit for IGF-II. In summary, IGF-II rather than IGF-I is the predominant growth factor produced by OS cells, and three different receptors (IR-A, HR^A, and IGFIR) act complementarily for an IGF-II–mediated constitutive autocrine loop, in addition to the previously shown IGFIR/IGF-I circuit. Cotargeting IGFIR and IR-A is more effective than targeting IGF-IR alone in inhibiting OS growth. [Cancer Res 2009;69(6):2443–52]

Key Words: osteosarcoma, insulin receptor, insulin-like growth factor II

This article has been cited by other articles:

				A. Belfiore, F. Frasca, G. Pandini, L. Sciacca, and R. Vigneri Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease Endocr. Rev., October 1, 2009; 30(6): 586 - 623. [Abstract] [Full Text] [PDF]